The emerging role of metformin in gestational diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 19, Issue 6, 2017, Pages 765-772

  Gray, Susan G ^a   McGuire, Treasure M ^a,b,e   Cohen, Neale ^c   Little, Peter J ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d SUN YAT SEN UNIVERSITY   (China)

^e BOND UNIVERSITY   (Australia)

Author keywords

diabetes in pregnancy; gestational diabetes mellitus; insulin; metformin; pharmacology; therapeutics

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; ANTIDIABETIC AGENT;

DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; NONHUMAN; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; AUSTRALIA; CHEMICALLY INDUCED; PATHOPHYSIOLOGY; PREGNANCY OUTCOME; PRENATAL EXPOSURE;

AUSTRALIA; DIABETES, GESTATIONAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 85016323157     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12893     Document Type: Review

References (84)

1. Sharma A, Paliwal G, Upadhyay N, Tiwari A. Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. J Diabetes Metab Disord. 2015;14:15.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(suppl 1):S62-S67.
3. Campos C. Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. Postgrad Med. 2012;124:90-97.
4. Hod M. Advances in the understanding of diabetic embryopathy: signal transduction. Early Pregnancy. 1996;2:121-128.
5. American Diabetes Association. Standards of medical care in diabetes—2015 abridged for primary care providers. Clin Diabetes. 2015;33:97-111.
6. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5:355-366.
7. Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol. 2014;13:142.
8. Sheikh A. Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr. 2013;5:1-13.
9. Martis R, Brown J, Alsweiler J, Crawford TJ, Crowther CA. Different intensities of glycaemic control for women with gestational diabetes mellitus. Cochrane Database Syst Rev. 2016;(4):CD011624.
10. Vrachnis N, Antonakopoulos N, Iliodromiti Z, et al. Impact of maternal diabetes on epigenetic modifications leading to diseases in the offspring. Exp Diabetes Res. 2012;2012:538474.
11. Negrato CA, Mattar R, Gomes MB. Adverse pregnancy outcomes in women with diabetes. Diabetol Metab Syndr. 2012;4:41.
12. Zeng XL, Zhang YF, Tian Q, Xue Y, An RF. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. Medicine (Baltimore). 2016;95:e4526.
13. Nankervis A, McIntyre HD, Moses R, et al. ADIPS consensus guidelines for the testing and diagnosis of gestational diabetes mellitus in Australia. Consensus Guidelines for GDM. http://adips.org/information-for-health-care-providers-approved.asp. Accessed June 23, 2016.
14. International Association of Diabetes Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676-682.
15. World Health Organisation. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Geneva, Switzerland: WHO; 2013. http://www.who.int/diabetes/publications/Hyperglycaemia_In_Pregnancy/en/. Accessed June 17, 2016.
16. Nankervis AMH, Moses R, Ross GP, et al; for the Australasian Diabetes in Pregnancy Society. ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand. http://adips.org/information-for-health-care-providers-approved.asp. Accessed August 5, 2016.
17. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2014;38(suppl 1):S8.
18. Koning SH, Hoogenberg K, Lutgers HL, van den Berg PP, Wolffenbuttel BH. Gestational diabetes mellitus: current knowledge and unmet needs. J Diabetes. 2016;8:770-781.
19. Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. 2015;131(suppl 3):S173-S211.
20. Hughes RCE, Rowan J, Florkowski CM. Is there a role for HbA1c in pregnancy? Curr Diab Rep. 2016;16:5.
21. National Institute of Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. https://www.nice.org.uk/guidance/ng3/chapter/1-Recommendations#gestational-diabetes-2. Accessed June 9, 2016.
22. Feldman AZ, Brown FM. Management of type 1 diabetes in pregnancy. Curr Diab Rep. 2016;16:76.
23. American Diabetes Association. 12. Management of diabetes in pregnancy. Diabetes Care. 2014;38(suppl 1):S77.
24. Rudland VL, Hinchcliffe M, Pinner J, et al. Identifying glucokinase monogenic diabetes in a multiethnic gestational diabetes cohort: new pregnancy screening criteria and utility of HbA1c. Diabetes Care. 2015;39:50-52.
25. Murphy HR, Temple RC, Roland JM. Improving outcomes of pregnancy for women with type 1 and type 2 diabetes. Br J Diabetes Vasc Dis. 2007;7:38-42.
26. Ashrafi M, Sheikhan F, Arabipoor A, Hosseini R, Nourbakhsh F, Zolfaghari Z. Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS). Eur J Obstet Gynecol Reprod Biol. 2014;181:195-199.
27. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30(suppl 2):S112-S119.
28. Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol. 1999;180:903-916.
29. Chen X, Scholl TO. Association of elevated free fatty acids during late pregnancy with preterm delivery. Obstet Gynecol. 2008;112:297-303.
30. Kevat DA, Sinha AK, McLean AG. Lower treatment targets for gestational diabetes: is lower really better. Med J Aust. 2014;201:201-207.
31. Vaarasmaki M. Is it worth treating gestational diabetes: if so, when and how? Diabetologia. 2016;59:1391-1395.
32. Zhao LP, Sheng XY, Zhou S, et al. Metformin versus insulin for gestational diabetes mellitus: a meta-analysis. Br J Clin Pharmacol. 2015;80:1224-1234.
33. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53:809-820.
34. Feig DS, Murphy K, Asztalos E, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. BMC Pregnancy Childbirth. 2016;16:1-8.
35. Ibrahim MI, Hamdy A, Shafik A, Taha S, Anwar M, Faris M. The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial. Arch Gynecol Obstet. 2014;289:959-965.
36. Balsells M, Garcia-Patterson A, Sola I, Roque M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102.
37. Bergel R, Hadar E, Toledano Y, Hod M. Pharmacological management of gestational diabetes mellitus. Curr Diab Rep. 2016;16:118.
38. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003-2015.
39. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011;34:2279-2284.
40. Werner EA, Bell J. CCXIV. The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans. 1922;121:1790-1794.
41. Sterne J. Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage). Therapie. 1959;14:625-630.
42. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253-270.
43. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98.
44. DeFronzo RA, Buse JB, Kim T, et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016;59:1645-1654.
45. Stepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos. 2002;30:861-868.
46. Stepensky D, Friedman M, Srour W, Raz I, Hoffman A. Preclinical evaluation of pharmacokinetic–pharmacodynamic rationale for oral CR metformin formulation. J Control Release. 2001;71:107-115.
47. Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol. 1999;87:1990-1995.
48. Gong L, Goswami S Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. 2012;22:820-827.
49. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56:1898-1906.
50. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542-546.
51. Luengo A, Sullivan LB, Heiden MGV. Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol. 2014;12:82.
52. Sinai Talaulikar V, Tang T, Yasmin E. Role of metformin in women's health: review of its current place in clinical practice and emerging indications for future. Obstet Gynecol Surv. 2016;71:307-317.
53. Dujic T, Causevic A, Bego T, et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med. 2016;33:511-514.
54. Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010;38:833-840.
55. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117:1422-1431.
56. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015;64:1786-1793.
57. Bailey CJ, Wilcock C, Scarpello JHB. Metformin and the intestine. Diabetologia. 2008;51:1552.
58. Wouldes TA, Battin M, Coat S, Rush EC, Hague WM, Rowan JA. Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child. 2016. doi:10.1136/archdischild-2015-309602. [Epub ahead of print].
59. Zhu B, Zhang L, Fan YY, et al. Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials. Ir J Med Sci. 2016;185:371-381.
60. Feng Y, Yang H. Metformin - a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2016:1-8. doi:10.1080/14767058.2016.1228061. [Epub ahead of print].
61. Briggs GG, Freeman RK. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Philadelphia, PA: Lippincott Williams & Wilkins; 2014.
62. Therapeutic Goods Administration, Australian Government Department of Health. Prescribing medicines in pregnancy database. [updated 2016 June 1]. https://www.tga.gov.au/prescribing-medicines-pregnancy-database. Accessed June 27 2016.
63. Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism. 2013;62(11):1522-1534.
64. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86:658-663.
65. Nanovskaya TN, Nekhayeva IA, Patrikeeva SL, Hankins GD, Ahmed MS. Transfer of metformin across the dually perfused human placental lobule. Am J Obstet Gynecol. 2006;195:1081-1085.
66. Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS One. 2013;8:e64585.
67. Ainuddin JA, Karim N, Zaheer S, Ali SS, Hasan AA. Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. J Diabetes Res. 2015:325851:1-11. doi:10.1155/2015/325851.
68. Tertti K, Ekblad U, Koskinen P, Vahlberg T, Ronnemaa T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. Diabetes Obes Metab. 2013;15:246-251.
69. Kitwitee P, Limwattananon S, Limwattananon C, et al. Metformin for the treatment of gestational diabetes: an updated meta-analysis. Diabetes Res Clin Pract. 2015;109:521-532.
70. Rowan JA, Gao W, Hague WM, McIntyre HD. Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial. Diabetes Care. 2010;33:9-16.
71. Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214:356.e1-356.e15.
72. Dallaglio K, Bruno A, Cantelmo AR, et al. Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis. 2014;35:1055-1066.
73. Simmons D. Metformin treatment for Type 2 diabetes in pregnancy? Best Pract Res Clin Endocrinol Metab. 2010;24:625-634.
74. Feig DS, Murphy K, Asztalos E, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. BMC Pregnancy Childbirth. 2016;16:173.
75. Vest AR, Cho LS. Hypertension in pregnancy. Curr Atheroscler Rep. 2014;16:395.
76. McGrath RT, Glastras SJ, Hocking S, Fulcher GR. Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. Diabetes Res Clin Pract. 2016;116:96-99.
77. Ashoush S, El-Said M, Fathi H, Abdelnaby M. Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus. J Obstet Gynaecol Res. 2016;42:640-647.
78. American College of Obstetrics and Gynacology. Practice Bulletin No. 137: gestational diabetes mellitus. Obstet Gynecol. 2013;122:406-416.
79. McElduff A, McIntyre HD, Lagström JA, et al. The Australasian Diabetes in Pregnancy Society consensus guidelines for the management of type 1 and type 2 diabetes in relation to pregnancy. Med J Aust. 2005;183:373-377.
80. Gestational Diabetes. Therapeutic Guidelines: Endocrinology. (eTG November 2015 edition). Melbourne, Australia: Therapeutic Guidelines Limited; 2015 November.
81. Kalra P, Anakal M. Peripartum management of diabetes. Indian J Endocrinol Metab. 2013;17(suppl 1):S72-S76.
82. Elmekkawi SF, Mansour GM, Elsafty MS, Hassanin AS, Laban M, Elsayed HM. Prediction of fetal hypertrophic cardiomyopathy in diabetic pregnancies compared with postnatal outcome. Clin Med Insights Womens Health. 2015;8:39-43.
83. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6.
84. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39:198-205.